Compare Stocks: TYRA, PTCT, ERAS, and CRSP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$51.78 +3.6%	$53.86	$44.12 ▼ $63.45	$5.01B	1.92	1.72 million shs	1.39 million shs
ERAS Erasca	$14.91 +1.8%	$15.35	$2.11 ▼ $24.28	$5.21B	0.68	5.79 million shs	3.50 million shs
PTCT PTC Therapeutics	$68.97 +1.2%	$65.12	$58.80 ▼ $90.87	$5.76B	0.52	1.36 million shs	1.34 million shs
TYRA Tyra Biosciences	$21.52 +0.7%	$22.48	$13.35 ▼ $40.65	$1.28B	0.65	897,177 shs	542,626 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	0.00%	-2.88%	-9.81%	-4.69%	-19.33%
ERAS Erasca	+4.20%	-3.81%	-0.68%	-21.37%	+515.13%
PTCT PTC Therapeutics	+11.89%	+9.71%	+7.34%	-1.57%	+0.28%
TYRA Tyra Biosciences	+0.19%	-0.70%	+4.60%	-16.88%	+38.50%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$51.78 +3.6%	$53.86	$44.12 ▼ $63.45	$5.01B	1.92	1.72 million shs	1.39 million shs
ERAS Erasca	$14.91 +1.8%	$15.35	$2.11 ▼ $24.28	$5.21B	0.68	5.79 million shs	3.50 million shs
PTCT PTC Therapeutics	$68.97 +1.2%	$65.12	$58.80 ▼ $90.87	$5.76B	0.52	1.36 million shs	1.34 million shs
TYRA Tyra Biosciences	$21.52 +0.7%	$22.48	$13.35 ▼ $40.65	$1.28B	0.65	897,177 shs	542,626 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	0.00%	-2.88%	-9.81%	-4.69%	-19.33%
ERAS Erasca	+4.20%	-3.81%	-0.68%	-21.37%	+515.13%
PTCT PTC Therapeutics	+11.89%	+9.71%	+7.34%	-1.57%	+0.28%
TYRA Tyra Biosciences	+0.19%	-0.70%	+4.60%	-16.88%	+38.50%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.60	Moderate Buy	$66.00	27.93% Upside
ERAS Erasca	2.64	Moderate Buy	$22.09	49.13% Upside
PTCT PTC Therapeutics	2.63	Moderate Buy	$95.71	39.75% Upside
TYRA Tyra Biosciences	2.93	Moderate Buy	$47.20	120.93% Upside

Current Analyst Ratings Breakdown

Latest TYRA, PTCT, ERAS, and CRSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/4/2026	CRSP CRISPR Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Equal Weight	$75.00 ➝ $70.00
11/3/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
11/3/2026	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$82.00
11/2/2026	PTCT PTC Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$108.00 ➝ $109.00
10/30/2026	PTCT PTC Therapeutics	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$90.00 ➝ $95.00
10/30/2026	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$109.00 ➝ $112.00
10/30/2026	PTCT PTC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Sector Perform	$75.00 ➝ $77.00
10/20/2026	PTCT PTC Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$106.00
10/16/2026	PTCT PTC Therapeutics	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Hold	$62.00
10/15/2026	CRSP CRISPR Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	TYRA Tyra Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 11/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$3.51M	1,421.15	N/A	N/A	$20.17 per share	2.56
ERAS Erasca	N/A	N/A	N/A	N/A	$1.05 per share	N/A
PTCT PTC Therapeutics	$1.73B	3.31	$9.87 per share	6.94	($2.29) per share	-29.91
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$4.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$581.60M	-$4.76	N/A	N/A	N/A	-1,812.07%	-24.96%	-17.91%	N/A
ERAS Erasca	-$124.55M	-$0.95	N/A	N/A	N/A	N/A	-38.43%	-32.05%	11/11/2026 (Estimated)
PTCT PTC Therapeutics	$682.64M	-$1.40	N/A	31.86	2.93	-9.17%	N/A	-0.10%	N/A
TYRA Tyra Biosciences	-$119.95M	-$2.40	N/A	N/A	N/A	N/A	-46.39%	-43.07%	11/4/2026 (Estimated)

Latest TYRA, PTCT, ERAS, and CRSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ERAS Erasca	-$0.1301	N/A	N/A	N/A	N/A	N/A
11/4/2026	Q3 2026	TYRA Tyra Biosciences	-$0.6687	N/A	N/A	N/A	N/A	N/A
11/2/2026	Q3 2026	CRSP CRISPR Therapeutics	-$1.06	-$1.15	-$0.09	-$1.15	$14.75 million	$12.67 million
10/29/2026	Q3 2026	PTCT PTC Therapeutics	$0.1434	-$0.62	-$0.7634	-$0.62	$306.43 million	$357.81 million
8/11/2026	Q2 2026	ERAS Erasca	-$0.1114	-$0.14	-$0.0286	-$0.14	N/A	N/A
8/4/2026	Q2 2026	TYRA Tyra Biosciences	-$0.6499	-$0.69	-$0.0401	-$0.69	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	0.34	17.85	17.85
ERAS Erasca	N/A	8.29	8.29
PTCT PTC Therapeutics	N/A	3.27	3.13
TYRA Tyra Biosciences	N/A	14.90	14.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
ERAS Erasca	67.78%
PTCT PTC Therapeutics	N/A
TYRA Tyra Biosciences	84.14%

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	5.20%
ERAS Erasca	14.20%
PTCT PTC Therapeutics	5.30%
TYRA Tyra Biosciences	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	393	96.69 million	91.67 million	Optionable
ERAS Erasca	103	349.76 million	300.10 million	Optionable
PTCT PTC Therapeutics	991	83.54 million	79.12 million	Optionable
TYRA Tyra Biosciences	87	59.68 million	52.22 million	Optionable

TYRA, PTCT, ERAS, and CRSP Headlines

Recent News About These Companies

Tyra Biosciences (TYRA) Set to Release Earnings on Wednesday

November 3 at 3:57 AM | americanbankingnews.com

Tyra Biosciences (TYRA) Stock Looks Rich Against Its Book Value

October 31, 2026 | finance.yahoo.com

Tyra Biosciences (TYRA) Set to Announce Quarterly Earnings on Wednesday

October 28, 2026 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Average Target Price of $47.20 According to Analysts

October 20, 2026 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Stock Jumps 4.4% - Here's Why

October 20, 2026 | marketbeat.com

Tyra Biosciences (TYRA) Stock Looks Expensive Against Its Book Value

October 17, 2026 | finance.yahoo.com

Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks

October 14, 2026 | zacks.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

October 13, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

October 8, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

October 6, 2026 | globenewswire.com

Raymond James Updates Healthcare Top Picks for October

October 3, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

October 1, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

September 29, 2026 | globenewswire.com

RA Capital Management Acquires Over 9 Million Derivative Securities in Tyra Biosciences (NASDAQ: TYRA)

September 20, 2026 | kalkinemedia.comK

Fuhrman Alan Acquires Additional 951 Shares, Holding 37,115 Tyra Biosciences Stocks Post-Award

September 20, 2026 | kalkinemedia.comK

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

September 17, 2026 | prnewswire.com

Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?

September 16, 2026 | insidermonkey.com

Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets

September 16, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

September 15, 2026 | globenewswire.com

Tyra Bioscience Shares Rise After Pricing $400 Million Offering

September 14, 2026 | marketscreener.comM

Tyra Biosciences Shares Rise After $400 Million Offering Prices

September 14, 2026 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TYRA, PTCT, ERAS, and CRSP Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

$51.78 +1.79 (+3.58%)

Closing price 04:00 PM Eastern

Extended Trading

$51.54 -0.23 (-0.45%)

As of 06:05 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Erasca NASDAQ:ERAS

$14.91 +0.27 (+1.84%)

Closing price 04:00 PM Eastern

Extended Trading

$15.77 +0.86 (+5.77%)

As of 06:02 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

PTC Therapeutics NASDAQ:PTCT

$68.97 +0.85 (+1.25%)

Closing price 04:00 PM Eastern

Extended Trading

$69.02 +0.05 (+0.07%)

As of 05:30 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Tyra Biosciences NASDAQ:TYRA

$21.52 +0.15 (+0.70%)

Closing price 04:00 PM Eastern

Extended Trading

$21.52 +0.00 (+0.02%)

As of 04:10 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TYRA, PTCT, ERAS, and CRSP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TYRA, PTCT, ERAS, and CRSP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TYRA, PTCT, ERAS, and CRSP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TYRA, PTCT, ERAS, and CRSP Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

Erasca NASDAQ:ERAS

PTC Therapeutics NASDAQ:PTCT

Tyra Biosciences NASDAQ:TYRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TYRA, PTCT, ERAS, and CRSP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TYRA, PTCT, ERAS, and CRSP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TYRA, PTCT, ERAS, and CRSP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TYRA, PTCT, ERAS, and CRSP Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

Erasca NASDAQ:ERAS

PTC Therapeutics NASDAQ:PTCT

Tyra Biosciences NASDAQ:TYRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools